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Background: We conducted a randomized, phase II, multicenter study to evaluate the anti-epidermal growth factor
receptor (EGFR) mAb panitumumab (P) in combination with chemoradiotherapy (CRT) with standard-dose capecitabine
as neoadjuvant treatment for wild-type KRAS locally advanced rectal cancer (LARC).
Patients and methods: Patients with wild-type KRAS, T3-4 and/or N+ LARC were randomly assigned to receive
CRT with or without P (6 mg/kg). The primary end-point was pathological near-complete or complete tumor response
(pNC/CR), deﬁned as grade 3 (pNCR) or 4 (pCR) histological regression by Dworak classiﬁcation (DC).
Results: Forty of 68 patients were randomly assigned to P + CRT and 28 to CRT. pNC/CR was achieved in 21
patients (53%) treated with P + CRT [95% conﬁdence interval (CI) 36%–69%] versus 9 patients (32%) treated with CRT
alone (95% CI: 16%–52%). pCR was achieved in 4 (10%) and 5 (18%) patients, and pNCR in 17 (43%) and 4 (14%)
patients. In immunohistochemical analysis, most DC 3 cells were not apoptotic. The most common grade ≥3 toxic
effects in the P + CRT/CRT arm were diarrhea (10%/6%) and anastomotic leakage (15%/4%).
Conclusions: The addition of panitumumab to neoadjuvant CRT in patients with KRAS wild-type LARC resulted in a
high pNC/CR rate, mostly grade 3 DC. The results of both treatment arms exceeded prespeciﬁed thresholds. The
addition of panitumumab increased toxicity.
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introduction
In patients with locally advanced rectal cancer (LARC),
complete surgical resection is a prerequisite for cure.
Neoadjuvant chemoradiotherapy (CRT) is frequently used to
downstage LARC tumors and to enable surgery to be more
effective and provide locoregional control [1–3]. The standard
neoadjuvant regimen is 5-ﬂuorouracil (5-FU) and external
radiotherapy (RT). Neoadjuvant CRT with capecitabine has
been shown to be tolerated with comparable activity to 5-FU
regimens [4, 5].
The epidermal growth factor receptor (EGFR)-targeted
monoclonal antibodies (mAbs) cetuximab and panitumumab
have shown efﬁcacy as monotherapy in phase III studies in
patients with chemotherapy-refractory metastatic colorectal
cancer [6–8] and also improved outcomes when added to
standard chemotherapy in the ﬁrst-line and subsequent lines of
therapy [7, 9, 10]. Preliminary data suggest that EGFR-targeted
agents in combination with RT may be synergistic, as RT
increases EGFR expression within tumor cells, while EGFR
blockade sensitizes the cells to the effects of RT [11, 12]. In the
setting of locally advanced head and neck cancer, addition of
cetuximab to RT enhanced locoregional control and survival
[13, 14].
Intensive research investigating the response according to
molecular tumor markers in order to allow better patient
selection, has shown that KRAS-activating mutations predict
resistance to cetuximab and panitumumab [15, 16]. Mutations
in KRAS codons 12 or 13 occur in ∼35%–45% of colorectal
cancers and lead to constitutive signaling via impaired ability
of GTPase-activating proteins to hydrolyze KRAS-bound
guanosine triphosphate (GTP) [17]. Other molecular markers
that have been linked to response/nonresponse to EGFR-
targeted mAbs in the colorectal cancer setting include
mutations of BRAF [18, 19] or PIK3CA [19], EGFR gene copy
number [20] and levels of EGFR ligands such as amphiregulin
(AREG) and epiregulin (EREG) [21].
We conducted a randomized, phase II, multicenter study to
evaluate the efﬁcacy and safety of panitumumab in
combination with capecitabine and external beam RT as a
neoadjuvant regimen for patients with advanced wild-type
KRAS LARC.
patients and methods
Patients with centrally tested wild-type KRAS LARC were recruited at
centers in Switzerland and from one center in Budapest, Hungary. The
study was conducted according to the Declaration of Helsinki. The
protocol was approved by the independent ethics committee at
participating centers. Patients provided written informed consent before
randomization. Separate informed consent was obtained for KRAS testing,
biobanking and translational research.
inclusion criteria
The eligibility criteria included: previously untreated histologically conﬁrmed
locally advanced adenocarcinoma of the rectum with or without nodal
involvement and requiring surgery; stage cT3/4 and/or cN1/2 cM0 and wild-
type KRAS gene status, as assessed by a central pathology; World Health
Organization (WHO) performance status 0–1; age ≥18 years and adequate
organ function. Patients with distant metastases were excluded from the study.
pretreatment evaluation
Baseline evaluation included computed tomography of the abdomen and
thorax, and magnetic resonance imaging of the pelvis.
KRAS mutation status and EGFR gene copy number analyses were
conducted at a central laboratory (Institute of Pathology, University of
Lausanne, CHUV, Switzerland), on formalin-ﬁxed parafﬁn-embedded
tissues (5 μm parafﬁn sections, microdissected to contain >70% tumor
tissues) prepared from diagnostic tumor biopsy samples collected before
the trial. The KRAS mutation status was analyzed by pyrosequencing of a
PCR-ampliﬁed exon 2 sequence containing codons 12 and 13. EGFR copy
number analysis was carried out by quantitative PCR of tumor DNA.
Serum samples were collected for KRAS mutational screening and
biomarker testing and were assessed at the laboratory of Molecular
Diagnostics, University Hospital Bern.
study conduct
After screening, the eligible patients were randomly assigned to receive
either CRT alone or panitumumab + CRT (P + CRT) as neoadjuvant
treatment. Randomization was stratiﬁed by: T-stage (T3 versus T4); tumor
localization (<10 cm versus ≥10 cm); institution and EGFR gene copy
number (<2.9 versus ≥2.9 copies per nucleus).
treatment
Panitumumab (6 mg/kg every 2 weeks for 8 weeks) was administered i.v.
over ∼60 min.
Capecitabine (825 mg/m2) was taken twice daily orally throughout RT.
RT was applied with a total dose of 45 Gy in 25 fractions of 1.8 Gy over 5
weeks, starting from 7 days after the ﬁrst panitumumab administration
(P + CRT arm) (supplementary Figure S1, available at Annals of Oncology
online). Patients were irradiated in the prone position using a linear
accelerator (3D-conformal or, preferably intensity-modulated, RT).
surgery and histopathology
Surgery was planned 6 weeks (±1 week) after completion of CRT. Total
mesorectal excision with sphincter preservation was to be carried out
whenever feasible, according to the standardized techniques, using a
laparoscopic or open approach. After ﬁxation and processing, resected
specimens were microscopically examined for the presence of tumor cells,
fully evaluated and staged according to the American Joint Committee on
Cancer TNM system [22]. Tumor regression was graded by the local
pathologists according to the regression grading scale proposed by Dworak
et al. [grade 0 = none; 1 = minimal; 2 =moderate (predominantly ﬁbrotic
changes with few tumor cells); 3 = good (very few tumor cells);
4 = complete (no tumor cells)] [23]. A central pathology review (by
F. Bosman, P. Yun) was carried out for samples classiﬁed as Dworak grade
2 or 3, as this cut-off was decisive regarding the primary end-point. Radical
resection (R0) was deﬁned as microscopic and macroscopic tumor-free
resection with clear circumferential resection margins (invasion front
≥2 mm from the lateral resection margin).
dose modiﬁcations
Chemotherapy and RT were interrupted if grade ≥3 toxicity developed
(capecitabine and panitumumab were also interrupted in case of diarrhea
and mucositis grade 2). Study treatment was restarted when toxicity had
resolved to grade ≤1. Dose reductions were required after grade ≥3
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toxicity. If the treatment was delayed for ≥2 weeks, the patient was
withdrawn from the study treatment.
adjuvant chemotherapy and follow-up evaluations
It was recommended that patients received adjuvant therapy for 4–6
months according to local practice. All patients with R0 resection were
followed (every 3 months during the ﬁrst year and every 6 months
thereafter) until disease progression or for 3 years after surgery.
concomitant therapy
All patients randomly assigned to panitumumab received a pre-emptive
supportive treatment regimen, consisting of a skin moisturizer, sunscreen
and doxycycline 100 mg orally twice daily.
study end-points
The primary end-point of the study was pathological near-complete or
complete tumor response (pNC/CR), prospectively deﬁned as grade 3
(near-complete) or 4 (complete) histological regression using the Dworak
classiﬁcation (DC) [23].
The early secondary end-points were R0 or R1 resection, sphincter
preservation, downstaging of primary tumor and/or lymph nodes
(comparison between cT/N and ypT/N) and postoperative complications
(within 8 weeks after surgery) deﬁned as insufﬁciency of anastomosis;
ﬁstula; severe local infection requiring antibiotics; bladder or erectile
dysfunction or need for additional interventions/operation. The late
secondary end-points (in the R0 population) were time (from
randomization) to local relapse, time to distant relapse and disease-free
survival.
translational studies
The following markers were evaluated in baseline serum (for full
methodological details, see supplementary information, available at Annals
of Oncology online): circulating tumor KRAS mutations by real-time
quantitative PCR and concentrations of EGFR and the related growth
factors AREG, betacellulin, epidermal growth factor (EGF), EGFR, EREG,
ﬁbroblast growth factor-basic, heparin-binding EGF-like growth factor
(HB-EGF), platelet-derived growth factor β polypeptide, placental growth
factor, tenascin C, transforming growth factor α and vascular endothelial
growth factor by using antibody suspension bead arrays and suspension
array system.
Pretreatment tumor specimens were examined for mutations in KRAS
exon 3 (codons 59 and 61), KRAS exon 4 (codons 117 and 146), BRAF
exon 15 (codon 600), NRAS exon 2 (codons 12 and 13), PIK3CA exon 9
(codons 542, 545 and 546) and PIK3CA exon 20 (codons 1043 and 1047)
(by pyrosequencing after PCR ampliﬁcation).
To assess the viability of the remaining tumor cells following
neoadjuvant treatment, the available post-surgery tumor specimens were
tested for the Ki-67 proliferation marker MIB-1 and the early apoptosis
marker M30 (by immunohistochemistry). Quantitative methylation
analysis of RASSF2A and EGFR promoter regions was also carried out (by
pyrosequencing after bisulﬁte modiﬁcation of genomic DNA and PCR
ampliﬁcation).
statistical considerations
The required sample size was calculated separately for each treatment arm
using the Fleming’s single-stage design [24] with 80% power and 5%
signiﬁcance level. For the P + CRT arm, 40 patients were required to test
the null hypothesis of the pNC/CR rate ≤10% versus the alternative of
≥25%. If there were ≤7 patients with pNC/CR, the treatment would not be
recommended for further investigation. Twenty-seven patients would be
needed in the CRT arm to test the null hypothesis of the pNC/CR rate
≤5% versus the alternative of ≥20%. Analyses of the primary end-point, as
well as pathological tumor response by the Dworak regression grade, were
based on the intention-to-treat analysis set (all randomly assigned
patients). The remaining early secondary end-points were based on the
resection population (all patients who underwent surgical resection).
Statistical comparisons between the treatment arms were not planned.
results
Between March 2009 and May 2010, a total of 68 patients (53
men and 15 women, aged 31–80 years) at 19 centers were
randomly assigned, 40 to P + CRT and 28 to CRT (Figure 1).
Most patients (n = 65) had WHO performance status 0. The
most common T-stage was cT3. The majority of patients had
tumor localization <10 cm from the anal margin, lymph node
involvement and <2.9 EGFR gene copies (Table 1).
treatment exposure
The median total CRT doses were similar in the P + CRT and
the CRT arms: RT 45 and 45 Gy; capecitabine 98% and 97% of
target dose; and panitumumab 88% of target dose. There were
four panitumumab dose delays (for diarrhea, and/or hand-foot
syndrome, n = 3; skin toxicity, n = 1) and 12 reduced/omitted
doses (mainly due to diarrhea or proctitis/ulceration, n = 6 or
skin toxicity/dry skin/erythema multiforme, n = 4).
surgery and outcomes
One patient (P + CRT) died of unknown causes and another
patient (CRT) was withdrawn from the study because of
incorrect diagnosis. A further eight patients stopped treatment
because of adverse events (P + CRT, n = 5; CRT, n = 1) or other
reasons, including patient’s wish or renal failure requiring
hospitalization (P + CRT, one patient each). A total of 66
patients underwent surgery (P + CRT, n = 39; CRT, n = 27).
A median of 15 lymph nodes per patient was harvested in both
the treatment arms. Tumor regression grade is shown in
Table 2 and achievement of the primary and early secondary
end-points is summarized in Table 3.
Complete regression by the Dworak criteria (grade 4) was
achieved in four patients (10%) and near-complete regression
(grade 3) in 17 patients (43%) in the P + CRT arm. In the CRT
arm, ﬁve patients (18%) and four patients (14%), respectively,
achieved complete and near-complete regression (Table 2).
A central pathology review for grade 2 or 3 regression was
completed for all but two patients (both in the P + CRT arm).
The primary end-point, pNC/CR, was achieved in 21 patients
(53%; 95% CI 36%–69%) in the P + CRT arm and 9 patients
(32%; 95% CI 16%–52%) in the CRT arm.
R0 resection was achieved in 33 patients (85%) in the
P + CRT arm and in 25 patients (93%) in the CRT arm.
Downstaging of the primary tumor and/or lymph nodes was
achieved in 34 patients (87%) and 23 patients (85%), with
sphincter preservation being achieved in 27 (69%) and 19
(70%) patients.
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postoperative complications
Postoperative complications are listed in Table 4. The most
common complications were anastomosis leakage, local
infection and requirement for further intervention/operation
[n = 7 patients each (18%) in the P + CRT arm versus 2, 4 and
4 patients (7%, 15% and 15%) in the CRT arm].
follow-up and deaths
The median follow-up time for 68 assessable patients was 9.1
months. So far only four patients died (two in each arm). Both
the patients in the P + CRT arm died perioperatively, whereas
the patients in the CRT arm died after tumor recurrences
during the follow-up phase. Both of the latter patients had R0
resection, but the circumferential resection margin was <2 mm
in one patient.
translational studies
The median EGFR gene copy number was 1.0. The EGFR copy
number did not associate with pNC/CR (data not shown).
Mutational analysis in tissue sections revealed a total of 23
Figure 1. Consort diagram.
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mutations in 18 tumors (26%), including 12 mutations in
KRAS exons 3 and 4, 7 mutations in PIK3CA, 2 mutations in
NRAS and 1 mutation in BRAF. Thirteen tumors harbored a
single mutation and ﬁve tumors had two concomitant
mutations in PIK3CA and KRAS (exons 3 and 4) (n = 4) and
NRAS (n = 1). There was no signiﬁcant association between
additional mutations and with pNC/CR (data not shown).
The RASSF2A promoter was hypermethylated in 75% of the
rectal tumors, but no signiﬁcant association was found with
pNC/CR (data not shown). In contrast, the EFGR promoter
was hypomethylated in all tumors.
The remaining tumor cells of the available specimens with
regression Dworak grade 3 showed no difference in MIB-1 and
M30 expression compared with those with regression Dworak
grades 0–2 for both the treatment arms (supplementary
Table S1, available at Annals of Oncology online).
No mutation of KRAS exon 2 (codon 12 and 13) was
detected in serum. None of the 12 serum biomarkers
analyzed were signiﬁcantly associated with pNC/CR
(supplementary Tables S2 and S3, available at Annals of
Oncology online).
Table 4. Number and percentage of patients with postoperative
complications within 8 weeks after surgery
Complication Panitumumab +
chemoradiotherapy
(CRT; n = 39)
CRT
(n = 27)
Total
(n = 66)
Anastomotic leakage 7 (18%) 2 (7%) 9 (14%)
Fistula 2 (5%) 2 (7%) 4 (6%)
Local infection 7 (18%) 4 (15%) 11 (17%)
Bladder dysfunction 3 (8%) 2 (7%) 5 (8%)
Erectile dysfunction 3 (8%) 3 (11%) 6 (9%)
Interventions/operation 7 (18%) 4 (15%) 11 (17%)
Other 6 (15%) 8 (30%) 14 (21%)
Table 2. Number and percentage of patients achieving each Dworak
regression grade (intent-to-treat analysis)
Dworak regression
grade
Panitumumab +
chemoradiotherapy
(CRT, n = 40)
CRT
(n = 28)
All
patients
(n = 68)
None (grade 0) 0 (0%) 1 (4%) 4 (6%)
Minimal (grade 1) 9 (23%) 11 (40%) 20 (29%)
Moderate (grade 2) 7 (18%) 6 (21%) 13 (19%)
Good (grade 3) 17 (43%) 4 (14%) 21 (31%)
Total (grade 4) 4 (10%) 5 (18%) 9 (13%)
Table 1. Baseline characteristics of patients
Panitumumab +
chemoradiotherapy
(CRT) (n = 40)
CRT
(n = 28)
All
patients
(n = 68)
Age (median/range) 62/31–80 60/35–77 61/31–80
Sex
Male 33 (82%) 20 (71%) 53 (78%)
Female 7 (18%) 8 (29%) 15 (22%)
World Health Organization (WHO) performance status
0 38 (95%) 27 (96%) 65 (96%)
1 2 (5%) 1 (4%) 3 (4%)
N stage
cN0 8 (20%) 7 (25%) 15 (22%)
cN1 24 (60%) 13 (46%) 37 (54%)
cN2 8 (20%) 8 (29%) 16 (24%)
T stageb
cT2 4 (10%) 2 (7%) 6 (9%)
cT3 34 (85%) 26 (93%) 60 (88%)
cT4 2 (5%) 0 (0%) 2 (3%)
Histological grade
G1 0 (0%) 2 (7%) 2 (3%)
G2 35 (88%) 23 (82%) 58 (85%)
G3 3 (8%) 3 (11%) 6 (9%)
Gx 2 (5%) 0 (0%) 2 (3%)
Tumor localizationa,b (cm)
<10 32 (80%) 22 (79%) 54 (79%)
≥10 8 (20%) 6 (21%) 14 (21%)
EGFR gene copy numberb
<2.9 38 (95%) 26 (93%) 64 (94%)
≥2.9 2 (5%) 2 (7%) 4 (6%)
Categorical parameters shown as frequency and percentage.
aIn centimeters from the anal verge.
bStratiﬁcation factor.
Table 3. Number and proportion of patients achieving primary and key
secondary end-points
No. of
patients
Percenta 95% CI
(exact)
Pathological near-complete or complete tumor response (pNC/CR)
Panitumumab +
chemoradiotherapy (CRT)
21/40 53 (36, 69)%
CRT 09/28 32 (16, 52)%
Total 30/68 44 (32, 57)%
R0 resectionb
Panitumumab + CRT 33/39 85 (70, 94)%
CRT 25/27 93 (76, 99)%
Total 58/66 89 (78, 95)%
Sphincter preservation
Panitumumab + CRT 27/39 69 (52, 83)%
CRT 19/27 70 (50, 86)%
Total 46/66 70 (57, 80)%
Downstaging of primary tumor or lymph nodes
Panitumumab + CRT 34/39 87 (73, 96)%
CRT 23/27 85 (66, 96)%
Total 57/66 86 (76, 94)%
Downstaging of primary tumor and lymph nodes
Panitumumab + CRT 16/39 41 (26, 58)%
CRT 08/27 30 (14, 50)%
Total 24/66 36 (25, 49)%
CI, conﬁdence intervals.
aBased on the intent-to-treat population for pCR and the operated
population for the remaining end-points.
bOnly one patient (from arm A) had R1 resection.
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tolerability
All 68 patients were assessable for safety. The most common
CTC grade ≥3 toxic effects in the P + CRT and the CRT arm
were: diarrhea (10% and 4% of patients), hand-foot syndrome
(2% and 0%), fatigue (2% and 0%), acneiform skin rash (2%
and 0%) and leakage (15% and 4%) (Table 5; grade 1–2 toxic
effects also shown).
Adverse events led to treatment discontinuation in ﬁve
patients in the P + CRT arm (diarrhea, enterocolitis, ulceration/
proctitis, dry skin, erythema multiforme/pruritus /itching) and
one patient in the CRT arm (cardiac arrest). Seventeen patients
had 18 serious adverse events [12 patients (30%) in the
P + CRT arm, ﬁve patients (18%) in the CRT arm]. Of these
events, three in the P + CRT arm and two in the CRT arm
were classiﬁed as clearly related to treatment. There were two
deaths during the safety monitoring period, both in the
P + CRT arm: from acute cardiac failure and sepsis resulting
from anastomatic leakage, respectively.
discussion
In patients with LARC, the rates of pCR have generally been
low (<10%) with neoadjuvant regimens consisting of CRT and
cetuximab [25–30]. It is possible that this might reﬂect issues
such as the type of chemotherapy used, dosage and scheduling.
Moreover, these studies did not preselect patients with wild-
type KRAS tumors. However, two studies using combination
chemotherapies with EGFR-targeted Mab achieved pCR rates
of >20% [31, 32].
Our study investigated the addition of panitumumab to
neoadjuvant capecitabine and external RT. Using a prospective
approach we excluded patients with tumors harboring KRAS
mutations. Although KRAS testing is now integrated into
clinical practice before the initiation of cetuximab or
panitumumab treatment in patients with metastatic colorectal
cancer [33, 34], the role of KRAS mutations in determining the
response to EGFR-targeted mAbs in the neoadjuvant setting is
less clear. In a number of phase II studies in LARC, which did
not select patients by KRAS status, including the StarPan/
STAR-02 study, KRAS and/or BRAF mutations did not
correlate with pCR after neoadjuvant treatment containing
cetuximab or panitumumab, probably because of low numbers
of patients in these studies [31, 32, 35–38].
The primary end-point of our study was pNC/CR, deﬁned
as Dworak grade 3, as well as grade 4 tumor regression. This is
based on the previous data showing that Dworak grade 3 in
this setting may confer a similar clinical prognosis to complete
response [39, 40]. In the P + CRT arm, there were 4 grade 4
(10%) and 17 grade 3 regressions (43%), compared with only 5
grade 4 (18%) and 4 grade 3 (14%) regressions in the CRT
arm, for pNC/CR rates of 53% and 32%. Central pathology
review was mandatory for all tumors with Dworak grade 2 or 3
regression. Our M30/Ki-67 results indicate that most of the
remaining tumor cells are not apoptotic and show proliferation
rates in the range of untreated tumors. This ﬁts with the cancer
stem cell hypothesis, in that eradication of responsive cancer
cells leaves behind a cancer cell population with clonogenic
potential. Although this was true for both the treatment arms,
it was more pronounced in the P + CRT arm in which the high
pNC/CR rate was mainly achieved by Dworak grade 3
(Table 2). In the light of the ongoing debate regarding the
validity of pCR as a surrogate end-point in rectal cancer trials,
our results point out the fact that pCR (deﬁned as Dvorak
grade 4) only reﬂects a part of the possible destruction
following neoadjuvant treatment schedules. This might at least
partly explain why in the EXPERT-C trial the pCR was not
affected by the addition of cetuximab, whereas the response
rate and overall survival were changed signiﬁcantly [38].
As this was a phase II trial with two parallel treatment arms,
formal statistical comparisons between the two treatment arms
were not conducted. We included a standard arm in this trial
for calibration purposes and to avoid biases due to patient
selection and heterogeneous medical care.
The StarPan/STAR-02 study achieved a 21% pCR rate (12/57
patients; 95% CI 10%–32%) based on complete tumor
regression (ypT0N0) with a neoadjuvant regimen of
panitumumab, 5-FU and oxaliplatin-RT [32]. Grade 3–4
diarrhea occurred in 39% of the patients with one toxic death,
and grade 3/4 skin toxicity in 19% of the patients [32]. In our
study, all the patients randomly assigned to P + CRT received a
pre-emptive supportive treatment including oral doxycycline.
Such measures have been shown to markedly reduce the
incidence of skin toxicity and diarrhea associated with
panitumumab [41]. Grade 3–4 diarrhea occurred in 10% of
our patients, with grade 3–4 acneiform rash in only 2%.
Postoperative complications were relatively common in the
P + CRT arm. The rate of postoperative anastomotic leakage
that we encountered (18% of patients) with one patient
developing fatal sepsis is in the upper range [42–44] of the
reported literature. In our study, panitumumab was continued
until 2 to 3 weeks before surgery and this may have delayed the
Table 5. Number and percentage of patients with most common grade 3–4 or 1–2 toxicities by common terminology criteria for adverse events
Grade 3–4 Grade 1–2
Panitumumab + chemoradiotherapy
(CRT; n = 40)
CRT (n = 28) Panitumumab + CRT (n = 40) CRT (n = 28)
Diarrhea 4 (10%) 1 (4%) 29 (73%) 15 (54%)
Hand-foot syndrome 1 (2%) 0 (0%) 6 (15%) 4 (14%)
Fatigue 1 (2%) 0 (0%) 18 (45%) 9 (32%)
Acneiform skin rash 1 (2%) 0 (0%) 14 (35%) 0 (0%)
Nausea 0 (0%) 0 (0%) 10 (25%) 6 (21%)
Anastomotic leakage 6 (15%) 1 (4%) 1 (3%) 1 (4%)
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healing process, thus contributing to additional perioperative
toxicity.
None of the mutations in the genes belonging to the EGFR
pathway were associated with the response to panitumumab.
The rate of BRAF mutations in our series of rectal cancers
(1.5%) as in the EXPERT-C trial [38] is signiﬁcantly lower
than the rates reported in colon cancers (5%–12%) [19, 45].
This was expected, since BRAF mutations are generally
associated with tumors with microsatellite instability, which are
mainly localized in the proximal colon.
In conclusion, this study showed that the addition of
panitumumab to neoadjuvant CRT in patients with KRAS
wild-type LARC resulted in a high pNC/CR rate, mostly grade
3 DC. The results of both the treatments exceeded prespeciﬁed
thresholds and are promising for the experimental arm. The
addition of panitumumab was well tolerated but increased
toxicity. More vigorous validation of these results is required in
a phase III trial.
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Her2/neu testing in gastric cancer: evaluating the risk
of sampling errors
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Background: We evaluated the risk of sampling errors in specimens of biopsy size, which may be caused by
heterogeneous overexpression of Her2/neu in gastric cancer (GC).
Patients and methods: The study cohort comprised 454 gastrectomy patients with adenocarcinoma of the stomach
or esophago-gastric junction. Tissue micro-arrays (TMAs) served as ‘biopsy procedure’ and were generated from
formalin-ﬁxed and parafﬁn-embedded tissue: ﬁve tissue cylinders were collected randomly from each tumor, rendering
2230 core cylinders. These were compared with 454 whole tissue sections obtained from the same parafﬁn blocks.
Her2/neu expression and gene ampliﬁcation were analyzed by immunohistochemistry and in situ hybridization. The
Her2/neu status was determined according to GC scoring system by two independent observers.
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